Dendrite Signs Comprehensive Software Services Agreement with Esprit Pharma; Esprit Looks to Dendrite's WebForce™ Express and Full Suite of Sales Support Services to Help Foster Growth and Market Expansion

Business Wire, August 23, 2005

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of sales, marketing, clinical and compliance solutions for the life science and pharmaceutical industries, today announced that Esprit Pharma, Inc. has signed a comprehensive, three-year several million dollar software and services agreement with Dendrite. This customer win was previously disclosed on Dendrite's quarterly earnings call, last month. Esprit Pharma, a specialty pharmaceutical company focused on the development of specialty therapeutics to improve patient outcomes in the urology area, selected Dendrite's First Source(TM) Sales Support, Validator(TM) data-cleansing services and WebForce(TM) Express for its sales force, to help drive more targeted marketing and sales of SANCTURA(TM), an overactive bladder medication.

"After securing the marketing rights to the new drug SANCTURA, it was critical, that as an emerging pharmaceutical company, we had the support infrastructure in place to drive sales and succeed in the highly competitive overactive bladder medication market," said Martin Silverman, executive director, sales and marketing operations at Esprit Pharma. "Dendrite provides our sales and marketing people with immediate value because their solutions are designed specifically for the pharmaceutical industry. Dendrite's industry knowledge will be critical as we continue to expand."

Dendrite's solutions will enable Esprit to develop an understanding of their customers and support services and to enhance their sales and marketing efficiencies. Esprit Pharma will utilize Dendrite's full First Source(TM) Sales Support Services suite, which includes Help Desk, Hardware and Asset Management, Account Management and Computer Systems services. These services will streamline the sales process to bring new levels of effectiveness to sales representatives in the field. In addition, Dendrite will also provide Esprit Pharma with its Validator data-cleansing services that verify and validate prescribers by license data, enabling the Esprit sales force to ensure that only valid and current prescribers are sampled.

"We are pleased that Esprit Pharma has selected Dendrite to help drive growth of SANCTURA while supporting its expanding sales force and its business initiatives," said Bob Parisi, senior vice president, Dendrite International, Inc. "Esprit Pharma's trust in Dendrite to support its sales goals demonstrates our continuous efforts to serve both specialty pharma as well as the big industry players."

About Dendrite

Founded in 1986, Dendrite International Inc, (NASDAQ: DRTE) provides diversified sales, marketing, clinical and compliance solutions to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

About Esprit Pharma

Esprit Pharma is niche oriented pharmaceutical company focused on specialty therapeutics to improve patient outcomes in the urology therapeutic area. The company focuses on exploring and identifying opportunities to selectively acquire and enhance the market potential of novel, commercially available therapeutics and late-stage development drugs addressing the needs of its market space.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.